Prostate Suite
End- to-end, AI-powered prostate MRI workflow, from interpretation to biopsy planning
An AI-powered suite of modular applications that streamline prostate MRI interpretation, analysis, and biopsy planning workflows. The solution integrates automated lesion detection and risk classification, intelligent gland segmentation with PSA density calculation, and PI-RADS-compliant reporting into a single platform.
Book a demo
Discover a New Standard of AI-Powered Care at RSNA 2025
Enhanced efficiency in prostate cancer diagnosis
Aids detection and characterization of suspicious prostate cancer lesions on MRI with automated ROI candidate identification and per-lesion risk classification at high sensitivity.
Automates PSA density calculation using accurate prostate volume measurements from gland segmentation.
Automatically contours the prostate gland and lesion ROI candidates, providing precise volume measurements while allowing manual refinement when needed.
Supports consistent lesion evaluation and biopsy recommendations for PI-RADS assessment with key findings and sector maps automatically pre-populated in structured reporting.
Compatible with most leading biopsy platforms
From initial scan review to targeted biopsy handoff, the solution connects seamlessly with 9+ fusion biopsy systems, eliminating manual data transfer while supporting radiologists at every step.
Koelis 3D Prostate Suite
MIM Symphony
Surgical BioBot Uro Fusion
Esaote MyLab X9 Fusion
Focal Healthcare
Medcom BiopSee
Navigo
Focalyx
BioJet
Exact Imaging
Proof in practice Evidence, Experience and Resources
27%
more lesions detected (sensitivity improved from 0.48 to 0.61)1
65%
reduction in segmentation variability among radiologists1
15%
improvement in overall radiologist performance1
37%
reduction in workflow time2 for biopsy-recommended cases
Real voices.
Real impact.
John Melnick, MD
Medical Director, Lenox Hill Radiology
"DeepHealth Prostate makes me faster and more efficient, particularly when l'm looking at harder-to-see areas. I can segment a lesion and push it over to biopsy in an instant."
Transforming population health with AI-powered diagnostic screening programs
Explore our visionCould healthcare begin before illness ever shows up? Rather than waiting for patients to experience symptoms, what if care started with prevention, early detection, and access to critical diagnostic tools?
Finding and treating diseases, like cancer, at earlier stages increases survival rates.3 Screening healthy people helps make early detection more possible. By expanding screening for a range of diseases, more people have the chance to stay healthy longer—and this shift has the potential to significantly transform population health.
Population Health Suite of Solutions
Orchestrate and scale high-volume cancer screening and disease assessment programs.
Find out more[2] Guenzel et al. “Diagnostic Utility of Artificial Intelligence–assisted Transperineal Biopsy Planning in Prostate Cancer Suspected Men: A Prospective Cohort Study.” Euro Urology Focus. Sep 2024.
[3] American Cancer Society. Breast Cancer Screening Guidelines, December 2023. Available on the https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html. (Accessed July 16, 2025)
Disclaimers: DeepHealth Prostate Suite comprises multiple applications including Quantib Prostate, DeepHealth Prostate AI and DeepHealth Viewer. Quantib Prostate is Manufactured by Quantib BV and distributed by DeepHealth, Inc, in the US. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. DeepHealth Prostate AI is FDA 510(k) pending Any claims made about Prostate Suite may reference claims associated with its individual components. Not all products and functionalities are commercially available in all countries. For clearance and commercial availability in your geography of functionalities listed and compatibility with other systems, please contact your account manager.